Published in Cancer on August 01, 2003
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol (2004) 1.91
Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol (2004) 1.88
Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol (2005) 1.51
Molecular functions of syndecan-1 in disease. Matrix Biol (2011) 1.47
Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer. World J Gastroenterol (2005) 1.45
Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? J Anat (2004) 1.39
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res (2007) 1.35
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res (2011) 1.11
Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer (2011) 1.10
Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res (2008) 1.09
Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal (2009) 1.04
Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Rev (2011) 1.04
Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia (2010) 1.02
Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer (2005) 1.01
Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem (2011) 1.00
Proteoglycans in prostate cancer. Nat Rev Urol (2012) 0.99
RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene (2013) 0.96
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer (2008) 0.95
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta (2015) 0.92
Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res (2009) 0.91
Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One (2013) 0.89
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Breast Cancer (Dove Med Press) (2012) 0.87
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther (2006) 0.87
Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci (2015) 0.86
Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers (2013) 0.85
Establishment and characterization of a high metastatic potential in the peritoneum for human gastric cancer by orthotopic tumor cell implantation. Dig Dis Sci (2007) 0.85
Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β. Aging (Albany NY) (2016) 0.84
High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women. BMC Cancer (2013) 0.83
Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity. J Cell Biochem (2014) 0.82
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Res (2011) 0.81
Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-β autocrine loop. Oncotarget (2016) 0.81
Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clin Exp Metastasis (2013) 0.80
Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations. J Cancer Res Clin Oncol (2006) 0.80
The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans. Biomed Res Int (2014) 0.80
Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breast. World J Surg Oncol (2013) 0.79
Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed Res Int (2013) 0.79
Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer (2014) 0.79
Over-sulfated glycosaminoglycans are alternative selectin ligands: insights into molecular interactions and possible role in breast cancer metastasis. Clin Exp Metastasis (2013) 0.78
Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions. Semin Cell Dev Biol (2009) 0.78
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. J Hematol Oncol (2013) 0.77
MiR-302a inhibits the tumorigenicity of ovarian cancer cells by suppression of SDC1. Int J Clin Exp Pathol (2015) 0.76
Decidualization and syndecan-1 knock down sensitize endometrial stromal cells to apoptosis induced by embryonic stimuli. PLoS One (2015) 0.76
Potential signaling pathway involved in sphingosine-1-phosphate-induced epithelial-mesenchymal transition in cancer. Oncol Lett (2016) 0.76
The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle. Reprod Biol Endocrinol (2010) 0.76
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget (2015) 0.76
The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma. J Gynecol Oncol (2010) 0.75
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer (2017) 0.75
Syndecan-1-Induced ECM Fiber Alignment Requires Integrin αvβ3 and Syndecan-1 Ectodomain and Heparan Sulfate Chains. PLoS One (2016) 0.75
Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer. F1000Res (2016) 0.75
Immunohistochemical analysis of syndecan-1 in leukoplakia and oral submucous fibrosis. Dent Res J (Isfahan) (2013) 0.75
Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. Breast Cancer Res (2017) 0.75
Syndecans as Cell Surface Receptors in Cancer Biology. A Focus on their Interaction with PDZ Domain Proteins. Front Pharmacol (2016) 0.75
Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singapore Med J (2014) 0.75
A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med (2003) 11.93
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol (2003) 4.31
Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol (2013) 4.21
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology (2007) 3.73
Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol (2009) 3.67
Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg (2010) 3.61
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med (2012) 3.27
Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol (2006) 3.26
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20
Smoking and colorectal cancer: a meta-analysis. JAMA (2008) 3.19
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res (2007) 3.12
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology (2010) 2.87
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 2.77
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Tobacco smoking and cancer: a meta-analysis. Int J Cancer (2008) 2.64
Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol (2007) 2.40
MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer (2008) 2.37
Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol (2006) 2.36
Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg (2008) 2.29
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol (2008) 2.18
Assessment of risk associated with specific fatty acids and colorectal cancer among French-Canadians in Montreal: a case-control study. Int J Epidemiol (2003) 2.11
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica (2007) 2.05
Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia (2005) 2.03
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation (2005) 2.01
Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat (2006) 1.99
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst (2006) 1.99
Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology (2007) 1.98
Tattoo ink-related cutaneous pseudolymphoma: a rare but significant complication. Case report and review of the literature. Aesthetic Plast Surg (2014) 1.98
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood (2011) 1.96
Robotic lobectomy for non-small cell lung cancer (NSCLC): long-term oncologic results. J Thorac Cardiovasc Surg (2011) 1.94
Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol (2010) 1.93
Four-arm robotic lobectomy for the treatment of early-stage lung cancer. J Thorac Cardiovasc Surg (2009) 1.91
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol (2005) 1.88
Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol (2003) 1.84
A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med (2011) 1.83
Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat (2007) 1.82
A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell (2012) 1.81
Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol (2005) 1.80
Helicobacter pylori and the risk of benign and malignant biliary tract disease. Cancer (2002) 1.78
Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis (2009) 1.75
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat (2008) 1.62
Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol (2010) 1.61
Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol (2009) 1.60
Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat (2010) 1.59
Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology (2003) 1.59
Does cytotechnician training influence the accuracy of EUS-guided fine-needle aspiration of pancreatic masses? Dig Liver Dis (2012) 1.58
The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. Clin Gastroenterol Hepatol (2009) 1.58
ABO blood group and cancer. Eur J Cancer (2010) 1.57
Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria? Eur J Cardiothorac Surg (2011) 1.56
Follow-up of exocrine pancreatic function in type-1 diabetes mellitus. Digestion (2005) 1.56
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med (2009) 1.54
High serum creatinine in acute pancreatitis: a marker for pancreatic necrosis? Am J Gastroenterol (2009) 1.52
Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"? Breast (2013) 1.51
Low fecal elastase 1 levels do not indicate exocrine pancreatic insufficiency in type-1 diabetes mellitus. Pancreas (2008) 1.48
Evolution of emphysema in relation to smoking. Eur Radiol (2009) 1.47
Transformation of normal human cells in the absence of telomerase activation. Cancer Cell (2002) 1.47
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol (2006) 1.47
Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol (2005) 1.47
Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol (2004) 1.46
Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg (2005) 1.45
Environmental factors and risk of pancreatic cancer. Pancreatology (2003) 1.45
Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer (2008) 1.45
Natural history of acute pancreatitis: a long-term population-based study. Am J Gastroenterol (2009) 1.44
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood (2008) 1.43
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol (2009) 1.43
High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biol Ther (2008) 1.42
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol (2004) 1.42
Glycemic index, glycemic load, and cancer risk: a meta-analysis. Am J Clin Nutr (2008) 1.41
Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer (2005) 1.40
Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plast Reconstr Surg (2017) 1.38
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 1.38
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer (2010) 1.38
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 1.37